ENTX vs. KRRO, RVNC, CTNM, GLUE, RGNX, ALMS, TSHA, CRVS, PGEN, and TNGX
Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Korro Bio (KRRO), Revance Therapeutics (RVNC), Contineum Therapeutics (CTNM), Monte Rosa Therapeutics (GLUE), REGENXBIO (RGNX), Alumis (ALMS), Taysha Gene Therapies (TSHA), Corvus Pharmaceuticals (CRVS), Precigen (PGEN), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.
Entera Bio vs.
Entera Bio (NASDAQ:ENTX) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
Korro Bio's return on equity of -50.25% beat Entera Bio's return on equity.
14.1% of Entera Bio shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 10.9% of Entera Bio shares are held by insiders. Comparatively, 5.4% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Entera Bio received 155 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 67.55% of users gave Entera Bio an outperform vote.
Entera Bio has higher revenue and earnings than Korro Bio.
Entera Bio has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.
In the previous week, Korro Bio had 3 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for Korro Bio and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.45 beat Korro Bio's score of 0.35 indicating that Entera Bio is being referred to more favorably in the media.
Entera Bio presently has a consensus price target of $10.00, suggesting a potential upside of 327.35%. Korro Bio has a consensus price target of $144.00, suggesting a potential upside of 289.19%. Given Entera Bio's higher probable upside, analysts plainly believe Entera Bio is more favorable than Korro Bio.
Summary
Korro Bio beats Entera Bio on 8 of the 15 factors compared between the two stocks.
Get Entera Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entera Bio Competitors List
Related Companies and Tools
This page (NASDAQ:ENTX) was last updated on 1/21/2025 by MarketBeat.com Staff
